There is a potential minimal risk of drug interaction between the two meds, and it is advisable to get the right prescription from the medical specialist. Do not make a decision to coadminister these drugs on your own since the effects can be harmful. Prior to using Truvada with Prezcobix pills, it’s necessary to have your health assessed from a healthcare provider.
Truvada belongs to the NRTI class of drugs. It has two active components: emtricitabine and tenofovir DF. Truvada is approved as a first-choice PrEP remedy alongside other safer sex prevention methods in uninfected individuals who are highly exposed to virus acquisition.
It can also be used for occupational or nonoccupational PEP in combination with other medicines that have different mechanisms of action (i.e. a protease inhibitor or integrase inhibitor).
It’s also prescribed as an anti-HIV treatment in combination with other ARV medications to prevent the spread of the virus in the body of HIV infected individual .
Prezcobix is a highly effective medicine approved to be combined with other antiretroviral meds for the treatment of HIV/AIDS in adult patients (either treatment-experienced or naïve). This medication is a combination of an HIV-1 protease inhibitor (darunavir) and a CYP3A inhibitor (cobicistat) as active substances.
Darunavir is a potent anti-HIV med designed specifically to control HIV that is resistant to some protease inhibitors. .
There is a potential interaction between EM/TDF and darunavir/cobicistat when coadministered with the quality of evidence being low since coadministration has not been studied.
From clinical tests, based on metabolism and clearance, there is no significant interaction between darunavir and emtricitabine. The latter is primarily renally excreted, and Prezcobix is unlikely to inhibit OCTs at any relevant concentrations.
On the other hand, Prezcobix is expected to increase tenofovir plasma concentrations (inhibition of P-gp). With this clinical evidence, Prezcobix and TDF can be used without dose adjustments, but renal function monitoring is necessary when darunavir/cobicistat is given in combination with TDF, especially in patients taking nephrotoxic agents and those with underlying systemic or renal problems.
Increased tenofovir plasma concentration may boost the risk for other tenofovir-related renal adverse conditions such as renal impairment, elevated creatinine, renal failure, and Fanconi syndrome.
If coadministering darunavir/cobicistat with tenofovir DF, dose adjustments are not necessary. However, if dose adjustment based on renal function, administering of cobicistat or cobicistat-containing regimens is not recommended in patients with CrCl less than 70 mL/min .